Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immunicum AB announces positive results for cancer vaccine INTUVAX in treatment of kidney cancer


Thursday, 5 Dec 2013 03:00am EST 

Immunicum AB:Says it announced positive survival data from a clinical phase I/II-study with the therapeutic cancer vaccine INTUVAX for the treatment of metastatic renal cancer.Says clinical phase I/II-study, initiated in Feb. 2012, includes 12 patients, each treated with two intratumoral injections/vaccinations with INTUVAX, two weeks apart, after which their cancer affected kidney, as part of the standard treatment, was surgically removed.Says vaccination with INTUVAX did not have any negative impact on patients' general condition and no serious vaccine-related adverse events have been reported.